Kelly J G, O'Malley K
Elan Corporation plc, Monksland, Athlone, Westmeath, Ireland.
Drugs Aging. 1993 Sep-Oct;3(5):400-7. doi: 10.2165/00002512-199303050-00002.
The calcium antagonists are associated with a number of advantages over other antihypertensive agents, such as a lack of metabolic, vascular and respiratory adverse events, yet are effective in reducing blood pressure. The currently available calcium antagonists are widely used, and new members, particularly of the dihydropyridine group, continue to emerge. These agents may well be considered for use in the management of hypertension and angina in elderly people. They undergo significant first-pass metabolism and tend to have high values of hepatic clearance with minimal amounts of unchanged drug in the urine. Plasma concentrations tend to be higher in elderly people and for that reason it may be prudent to initiate therapy with lower dosages. With this caveat, adverse effect profiles seem to be qualitatively and quantitatively similar in younger and older people. At equivalent plasma concentrations, the antihypertensive effect appears similar in young and elderly patients, and clinical studies point to comparable efficacy with other drug classes. Calcium antagonists do not have adverse renal, respiratory, cardiovascular, metabolic or peripheral vascular effects and therefore may be useful in patients with relevant concomitant disease.
与其他抗高血压药物相比,钙拮抗剂具有许多优势,例如没有代谢、血管和呼吸方面的不良事件,而且在降低血压方面有效。目前可用的钙拮抗剂被广泛使用,并且新的成员,特别是二氢吡啶类,不断涌现。这些药物很可能被考虑用于老年人高血压和心绞痛的治疗。它们经历显著的首过代谢,肝清除率往往较高,尿液中未变化的药物量极少。老年人的血浆浓度往往较高,因此谨慎起见,应以较低剂量开始治疗。尽管如此,年轻人和老年人的不良反应谱在定性和定量方面似乎相似。在等效血浆浓度下,年轻和老年患者的降压效果似乎相似,临床研究表明与其他药物类别具有相当的疗效。钙拮抗剂没有不良的肾脏、呼吸、心血管、代谢或外周血管作用,因此可能对患有相关合并症的患者有用。